Exhibit 99.1 Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights SAN DIEGO, November 6, 2025 – Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the third qu ...

Financial Performance - Revenues for Q3 2025 were approximately $14.2 million, a significant increase from $1.8 million in Q3 2024, and for the nine months ended September 30, 2025, revenues were $44.3 million compared to $4.5 million in the same period of 2024[86]. - Licensing revenue from the Novo Nordisk agreement contributed $13.2 million in Q3 2025 and $40.7 million for the nine months ended September 30, 2025[86]. - Net loss for Q3 2025 was $12.8 million, or $0.04 per diluted share, compared to a net loss of $64.8 million, or $0.18 per share, in Q3 2024[92]. - The accumulated deficit as of September 30, 2025, was approximately $2.0 billion, primarily due to research and development costs and administrative expenses[84]. Expenses - Research and development expenses decreased by 27% to $18.8 million in Q3 2025 from $25.8 million in Q3 2024, and for the nine months, they decreased by 14% to $49.8 million from $57.8 million[88]. - Selling, general and administrative expenses dropped 81% to $7.6 million in Q3 2025 from $39.6 million in Q3 2024, and for the nine months, they decreased 74% to $28.6 million from $110.8 million[89]. - The company used $50.6 million in cash from operations in the nine months ended September 30, 2025, primarily due to a net loss of $34.8 million, which included $9.7 million in non-cash stock-based compensation[96]. Cash and Investments - As of September 30, 2025, the company had $145.0 million in cash, cash equivalents, restricted cash, and short-term investments, down from $238.0 million as of December 31, 2024[96]. - The company anticipates that current cash and investment balances will be sufficient to fund operations for at least the next 12 months[106]. - The company has a financial covenant requiring a minimum balance of $29 million in a blocked account, which was maintained as of September 30, 2025[99]. - The company repaid $45 million to Oxford in April 2025 as part of a loan and security agreement amendment[98]. Regulatory and Product Development - The company received Fast Track designation from the FDA for pilavapadin, which is being developed for diabetic peripheral neuropathic pain[81]. - INPEFA (sotagliflozin) is commercially available in the U.S. and is approved to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure or type 2 diabetes[81]. - The company is pursuing regulatory approval for ZYNQUISTA (sotagliflozin) as a treatment for type 1 diabetes, with ongoing proceedings related to the FDA's complete response letters[77]. - Future capital requirements are expected to be substantial, influenced by ongoing R&D success, regulatory approvals, and new collaborations[105]. Licensing Agreements - The company entered into an exclusive license agreement with Novo Nordisk A/S in March 2025, receiving an upfront payment of $45 million for the development of LX9851[101]. - An exclusive license agreement with Viatris was established in October 2024, resulting in an upfront payment of $25 million for the commercialization of sotagliflozin outside the U.S. and Europe[102]. Financial Risks - The company is subject to interest rate sensitivity on outstanding Oxford Term Loans, which bear a floating rate tied to the 1-month CME Term SOFR rate[109]. - The company has not had material exposure to foreign currency rate fluctuations, as all sales have been made in U.S. dollars[110].

Exhibit 99.1 Ginkgo Bioworks Reports Third Quarter 2025 Financial Results Ginkgo provides an update on its third quarter financial results BOSTON, Mass – November 6, 2025 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the third quarter ended September 30, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Third Quarter 20 ...

Revenue and Profitability - Revenues increased by $34.8 million, or 51%, for the three months ended September 30, 2025, compared to the same period in 2024, primarily driven by $49.5 million of revenues related to the Edge Autonomy acquisition[183] - Gross profit for the three months ended September 30, 2025, was $16.8 million, representing a 40% increase compared to $12.0 million in the same period in 2024[182] - Gross profit decreased by $33.0 million, or 83%, for the nine months ended September 30, 2025, with gross margin dropping to 3% from 17%[195] - Adjusted EBITDA for the three months ended September 30, 2025, was $(2,569) thousand, compared to $2,440 thousand for the same period in 2024[207] Expenses - Selling, general and administrative expenses as a percentage of revenues increased to 49% for the three months ended September 30, 2025, from 26% during the same period in 2024[166] - Research and development expenses increased by 306% to $7.7 million for the three months ended September 30, 2025, compared to $1.9 million in the same period in 2024[182] - SG&A expenses rose by $32.8 million, or 187%, for the three months ended September 30, 2025, increasing as a percentage of revenue to 49% from 26%[186] - Interest expense, net increased by $24.1 million for the nine months ended September 30, 2025, primarily due to $20.0 million related to the repayment of the Seller Note[200] Losses - Net loss increased by $20.2 million for the three months ended September 30, 2025, compared to the same period in 2024, resulting in a net loss attributable to Redwire Corporation of $41.2 million[166][182] - The company recognized a net loss of $(141,079) thousand for the nine months ended September 30, 2025, compared to $(47,142) thousand for the same period in 2024[229] Contracts and Backlog - The book-to-bill ratio increased to 1.25 for the three months ended September 30, 2025, from 0.65 for the same period in 2024[166] - Total contracts awarded for the three months ended September 30, 2025, amounted to $129,800 thousand, compared to $44,503 thousand for the same period in 2024[210] - The contracted backlog as of September 30, 2025, was $355,628 thousand, an increase from $296,652 thousand as of December 31, 2024[216] - Organic backlog at the end of September 30, 2025, was $279,527 thousand, down from $296,652 thousand at the end of December 31, 2024[216] Cash Flow and Financing - Cash and cash equivalents as of September 30, 2025, were $52,300 thousand, with an additional $35,000 thousand available from existing credit facilities[220] - Net cash used in operating activities for the nine months ended September 30, 2025, was $(153,069) thousand, an increase of $128.7 million year-over-year[229] - Net cash used in investing activities increased by $166.2 million for the nine months ended September 30, 2025, primarily due to the Edge Autonomy acquisition and increased capital expenditures[232] - Net cash provided by financing activities increased by $286.6 million during the nine months ended September 30, 2025, driven by net proceeds from the issuance of common stock and exercise of warrants totaling $337.8 million[233] Other Financial Metrics - Other (income) expense, net decreased by $29.4 million for the nine months ended September 30, 2025, primarily due to a gain of $11.5 million from a decrease in the fair value of private warrant liability[201] - The effective tax rate decreased to (15.5)% for the nine months ended September 30, 2025, compared to (0.7)% for the same period in 2024[202] - The company recognized a gain of $11.5 million on the change in fair value of outstanding private warrants during the nine months ended September 30, 2025, compared to a loss of $8.1 million in 2024[231] Operational Highlights - The Company launched a total of 14 PIL-BOXes during the three months ended September 30, 2025, bringing the total number of PIL-BOX launches to 42[166] - The Company was awarded a contract to develop and deliver Roll-Out Solar Arrays for Axiom Space's first commercial space station module[166] - UAS deliveries during the three months ended September 30, 2025, included Stalker systems for the U.S. Army and Penguin systems for the Ukrainian Armed Forces[166] Accounting and Reporting - There were no material changes to critical accounting policies and estimates as disclosed in the audited financial statements[235] - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[236] - The increase in non-cash adjustments included depreciation and amortization expense of $11.7 million and share-based compensation of $39.5 million, primarily related to the Edge Autonomy acquisition[231] - The company experienced an increase in deferred tax benefit of $25.9 million year-over-year[231] - The company’s operations in Europe are primarily denominated in euros, limiting foreign currency exposure[234]

Financial Performance - The company reported net losses of $31.3 million and $84.5 million for the three and nine months ended September 30, 2025, compared to $29.5 million and $30.4 million for the same periods in 2024, indicating ongoing financial challenges [166]. - The company has never been profitable and may need additional financing to support ongoing operations and product development [166]. - For the nine months ended September 30, 2025, net cash used in operating activities was $58.3 million, compared to a net cash provided of $11.3 million for the same period in 2024 [214]. - The company anticipates ongoing operating losses due to substantial expenses related to the commercialization of NEXLETOL and NEXLIZET, as well as research and development activities [210]. - Interest expense for Q3 2025 was $22.1 million, an increase of $7.0 million from $15.1 million in Q3 2024, primarily due to interest on the term loan [193]. - Interest expense for the nine months ended September 30, 2025 was $62.0 million, an increase of approximately $19.2 million from $42.8 million in the same period of 2024, primarily due to interest on the term loan [201]. Product Development and Efficacy - NEXLETOL demonstrated an average 20.0% placebo-corrected LDL-C lowering in the CLEAR Outcomes trial, resulting in a 13% lower risk of major cardiovascular events versus placebo [167]. - NEXLIZET lowered LDL-C by a mean of 38% compared to placebo when added to maximally tolerated statins, showcasing its efficacy in cholesterol management [168]. - The FDA approved expanded indications for NEXLETOL and NEXLIZET in March 2024, enhancing their market potential [163]. - NILEMDO received an expanded indication from the EC in May 2024 to reduce cardiovascular risk in patients with or at high risk for ASCVD [169]. - The company continues to focus on commercializing NEXLETOL and NEXLIZET in the U.S. while pursuing other research and development activities [170]. Revenue and Sales - Product sales, net for Q3 2025 were $40.7 million, an increase of $9.6 million from $31.1 million in Q3 2024, primarily due to prescription growth of NEXLETOL and NEXLIZET [188]. - Collaboration revenue for Q3 2025 was $46.7 million, up approximately $26.2 million from $20.5 million in Q3 2024, driven by increased royalty sales growth and product sales to collaboration partners [189]. - Collaboration revenue for the three and nine months ended September 30, 2025, was primarily related to sales of bulk tablets and royalty revenue from collaboration partners [175]. - Product sales, net for the nine months ended September 30, 2025 were $115.8 million, an increase of approximately $31.6 million from $84.2 million in the same period of 2024 [196]. - Collaboration revenue for the nine months ended September 30, 2025 was $118.8 million, a decrease of $60.2 million from $179.0 million in the same period of 2024, mainly due to a prior settlement agreement [197]. Expenses and Costs - The company incurred $8.8 million in expenses related to ongoing clinical studies during the nine months ended September 30, 2025, up from $5.6 million in the same period of 2024 [172][173]. - Cost of goods sold for Q3 2025 increased to $41.3 million from $17.3 million in Q3 2024, an increase of $24.0 million, mainly due to higher product sales to collaboration partners [190]. - Cost of goods sold for the nine months ended September 30, 2025 was $101.4 million, an increase of $58.4 million from $43.0 million in the same period of 2024, attributed to increased product sales [198]. - Selling, general and administrative expenses for Q3 2025 were $41.8 million, up approximately $1.8 million from $40.0 million in Q3 2024, mainly due to increased legal and media costs [192]. - Research and development expenses for Q3 2025 were $14.1 million, an increase of $3.7 million from $10.4 million in Q3 2024, primarily due to costs for ongoing clinical studies [191]. Financing and Capital Structure - The company completed an underwritten public offering of 56,700,000 shares at $1.50 per share, resulting in net proceeds of approximately $90.7 million after deducting $7.1 million in underwriting discounts and expenses [208]. - The company issued $100.0 million in 5.75% Convertible Senior Subordinated Notes due in June 2030, exchanging approximately $210.1 million of 2025 Notes [209]. - The company entered into a Credit Agreement for a $150.0 million term loan, which was fully borrowed at closing, with an annual interest rate of 9.75% if paid in cash [220]. - Net cash provided by financing activities for the nine months ended September 30, 2025, was $6.0 million, primarily from the 2023 ATM program [216]. - The company repurchased Revenue Interests for $343.8 million, eliminating future payment obligations under the Revenue Interest Purchase Agreement [223]. Future Outlook and Risks - The company expects research and development expenses to increase in 2025 as it begins its phase III pediatric trial and progresses its preclinical pipeline [179]. - Current cash resources and future proceeds from product sales and collaboration agreements are estimated to be sufficient to fund operations for the foreseeable future [228]. - Future funding requirements will depend on various factors, including the successful development and commercialization of product candidates [230]. - The company anticipates financing cash needs through collaborations, strategic alliances, licensing arrangements, debt financings, and equity offerings [229]. - Potential dilution of stockholder ownership may occur if additional capital is raised through equity or convertible debt securities [229]. - The company may need to relinquish valuable rights to technologies or future revenue streams through collaborations or licensing arrangements [231]. - Adverse macroeconomic conditions could materially affect the ability to consummate equity or debt financing on favorable terms [231]. - There have been no off-balance sheet arrangements as defined by SEC rules during the reported periods [232]. - No material changes have occurred regarding market risk disclosures since the last annual report [233].

Company Overview - Lisata Therapeutics is a clinical stage pharmaceutical company focused on developing innovative therapies for cancer treatment, with a mission to improve patient outcomes [8][10]. - The company has a cash runway extending into Q1 2027 and operates with no debt, indicating strong financial health [15]. - Lisata's leadership team has extensive experience in global drug development, which is crucial for navigating the complexities of the pharmaceutical industry [12][18]. Product Development and Efficacy - Certepetide, a proprietary cyclic peptide, is designed to optimize solid tumor treatment by converting tumor stroma from a barrier to a conduit for anti-cancer drugs and selectively reducing immunosuppressive T cells [28][29]. - Certepetide improved median overall survival in metastatic pancreatic ductal adenocarcinoma (mPDAC) to 12.68 months compared to 9.23 months for standard of care (SoC) [92]. - In the ASCEND Phase 2b study, Certepetide demonstrated a median progression-free survival (PFS) of 7.46 months versus 5.29 months for SoC, nearing statistical significance (HR 0.61, p=0.09) [96]. - Certepetide showed a 55% improvement in overall survival compared to the historical control of gemcitabine plus nab-paclitaxel [77]. - Certepetide achieved a 45% objective response rate (CR + PR) in Cohort B compared to 19% in the placebo group [101]. - Certepetide demonstrated internal consistency across two Phase 1b/2a trials, supporting its efficacy in mPDAC [79]. - Certepetide demonstrated improved overall survival in metastatic pancreatic ductal adenocarcinoma (mPDAC) compared to standard of care, with median overall survival (mOS) of 10.32 months versus 9.23 months for the control group [107]. - In Cohort B, the median progression-free survival (mPFS) was 7.46 months for Certepetide compared to 5.29 months for placebo, with a hazard ratio (HR) of 0.61 and a p-value of 0.09 [107]. - The overall response rate (ORR) for Certepetide treated patients was 50.0%, significantly higher than the 21.1% for placebo, with 1 complete response observed in the Certepetide group [107]. - Certepetide was well tolerated, with adverse events (AEs) similar to those of standard of care, and the most common AEs included fatigue (73.85% in Cohort A) and nausea (53.85% in Cohort A) [105]. Clinical Trials and Studies - The ASCEND Phase 2b trial for first-line mPDAC has completed enrollment with 158 participants, testing gemcitabine/nab-paclitaxel with certepetide or placebo [189]. - The BOLSTER Phase 2a trial for cholangiocarcinoma has completed enrollment for both first-line and second-line cohorts, with a total of 69 participants [171]. - The CENDIFOX Phase 1b/2a trial for pancreatic, colon, and appendiceal cancers has completed enrollment with 50 participants [171]. - The ILSTA Phase 1b/2a trial for locally advanced, non-resectable PDAC has completed enrollment with 30 participants [171]. - The company is targeting mid-2026 for the final data from the BOLSTER trial, which is expected to be achieved 6 months early [175]. - The primary endpoints included Progression Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS) metrics [193]. - A Phase 1b/2a trial in China (CEND1-201) is evaluating the safety and preliminary efficacy of certepetide in 55 patients with mPDAC, with results expected to contribute to overall survival and disease control rates [193]. - The CENDIFOX trial aims to complete enrollment by Q4 2024, focusing on drug safety and overall response rates [197]. - The intervention arm of the Phase 2b study included 63 patients receiving two IV pushes of certepetide, while the control arm had 29 patients receiving placebo [191]. - The study design includes treatment on days 1, 8, and 15 every 28 days, allowing for consistent monitoring of patient responses [191]. - The trials are being conducted across approximately 30 sites, including locations in Australia and New Zealand [191]. - Preliminary data from the trials was presented at the 2023 ASCO Annual Meeting, indicating ongoing research and development efforts in the field [193]. Strategic Partnerships and Financials - Lisata has established partnerships with organizations such as Catalent, GATC Health Corp., and Qilu Pharmaceutical, which support the development and commercialization of Certepetide [32][34]. - The company is eligible to receive over $10 million in tiered development milestone payments from Catalent, along with revenue sharing on future sales [34]. - Certepetide has a robust intellectual property portfolio, including 25 granted patents and 26 pending patents, with market exclusivity of 7 to 10 years post-approval in the U.S. and EU [30]. - Lisata's strategic partnerships are expected to enhance the development of Certepetide and its combinations with other therapies, potentially leading to significant revenue growth [34]. - The company is exploring additional commercial partnership opportunities to expand the reach of Certepetide in various oncology applications [129]. - As of September 30, 2025, the company has $19.0 million in cash and investments, with no debt, providing a projected cash runway into 2027 [178]. - The company has 8.8 million common shares outstanding and 1.5 million options outstanding, with a weighted average exercise price of $40.52 for warrants [179]. Market Context and Future Outlook - The global cancer burden is projected to increase significantly, with an estimated 35 million new cases and 18.5 million deaths by 2050, highlighting the urgent need for effective cancer therapies [22][23]. - The company anticipates multiple product and business milestones over the next 12 months, indicating a proactive approach to market expansion [13]. - Certepetide's commercial prospects are bolstered by its applicability across various treatment lines for mPDAC, including first-line, second-line, and third-line therapies [123]. - Certepetide's development strategy includes rapid global registration and combination studies with various SoC regimens [71]. - The global Phase 3 trial design for Certepetide has been agreed upon with the FDA, targeting 657 patients and focusing on overall survival as the primary endpoint [134]. - Certepetide has received FDA Fast Track Designation and Orphan Drug Designations, enhancing its regulatory advantages and potential market access [130].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number: 001-40618 Stevanato Group S.p.A. (Translation of registrant's name into English) Table of Contents | | Page | | --- | --- | | Introduction | i | | Cautionary Statements Regarding Forward-Looking Statements | ii | | Unaudited Interim Condensed Consolidated Financial S ...

Financial Performance - Net income for the three months ended September 30, 2025, was $14,390, a 32.4% increase compared to $10,905 for the same period in 2024[10]. - Net income for the three months ended September 30, 2025, was $18,866,000, an increase of 29.8% compared to $14,567,000 for the same period in 2024[12]. - For the nine months ended September 30, 2025, net income reached $55,823,000, up 39.9% from $39,901,000 in the prior year[15]. - Net income for the nine months ended September 30, 2025, was $42,484,000, a 42% increase from $29,945,000 in 2024[23]. - Basic net income per common share increased to $1.43 for the three months ended September 30, 2025, up from $1.09 in 2024, a 31.1% rise[10]. - Basic net income per common share for the nine months ended September 30, 2025, was $4.23, up from $2.98 in 2024, marking a 42% increase[37]. - Diluted net income per common share for the nine months ended September 30, 2025, was $4.15, compared to $2.94 in 2024, also a 41% increase[37]. Asset and Liability Growth - Total assets increased to $2,876,365, up from $2,654,017, representing an 8.4% growth year-over-year[8]. - Total liabilities increased to $2,542,342, up from $2,358,434, reflecting a growth of 7.8% year-over-year[8]. - Total loans increased to $2,468,527, up 9.2% from $2,260,657 as of December 31, 2024[8]. - Total deposits grew to $2,267,484, an increase of 7.9% from $2,100,313 at the end of 2024[8]. - Shareholders' equity rose to $334,023, an increase of 13% from $295,583 at the end of 2024[8]. Income and Expense Analysis - Total interest income for Q3 2025 was $44,361, an increase of 12.5% compared to $39,550 in Q3 2024[10]. - Net interest income after provision for credit losses rose to $29,314, up from $23,776, reflecting a 23.3% increase year-over-year[10]. - Noninterest income for the nine months ended September 30, 2025, was $10,883, compared to $6,553 for the same period in 2024, marking a 66.5% increase[10]. - Total noninterest income for Q3 2025 was $2,967, compared to $2,803 in Q3 2024, reflecting a 5.8% growth[10]. Credit Losses and Provisions - The provision for credit losses on loans was $1,409 for the three months ended September 30, 2025, compared to $1,029 for the same period in 2024, indicating a 36.8% increase[10]. - The provision for credit losses charged to expense for the nine months ended September 30, 2025, was $4,491 thousand, compared to $1,937 thousand for the same period in 2024, representing an increase of approximately 132%[119]. - The allowance for credit losses was $30,245 thousand as of September 30, 2025, compared to $26,788 thousand at December 31, 2024[8]. Comprehensive Income - Total comprehensive income for the three months ended September 30, 2025, was $19,728,000, compared to $15,718,000 for the same period in 2024, reflecting a 25.7% increase[12]. - Total comprehensive income for the nine months ended September 30, 2025, included $275,000 in other comprehensive income, compared to a loss of $115,000 in the same period of 2024[20][23]. Shareholder Information - The company declared dividends on common stock of $0.15 per share for the three months ended September 30, 2025, compared to $0.13 per share in the same period of 2024[17]. - The total number of common shares outstanding as of September 30, 2025, was 10,041,000, slightly down from 10,063,000 a year earlier[17]. Fair Value Measurements - The fair value of the Company's available-for-sale (AFS) debt securities portfolio was $82.1 million, with most classified as Level 2 assets[47]. - The fair value of the Company's equity securities portfolio was $12.7 million, primarily classified as Level 1 assets[49]. - The fair value of loans, net of allowance for credit losses, was $2,422,861,000 as of September 30, 2025, compared to $2,221,706,000 at December 31, 2024, indicating an increase of approximately 9.0%[63]. - The total debt securities available for sale amounted to $82,063,000 as of September 30, 2025, a decrease from $93,884,000 as of December 31, 2024, representing a decline of approximately 12.6%[54]. Economic and Market Conditions - The company continues to assess the impact of macro-economic trends, including inflation and interest rate environments, on its operations[27]. - The company experienced fluctuations in collateral values and general economic conditions, affecting the risk of loss quantification[100].

Exhibit 99.1 Mac Schuessler, President and Chief Executive Officer stated "We are pleased with our third quarter results, which reflects our continued focus on operational excellence and strategic execution. By expanding our footprint in Latin America through the Tecnobank acquisition, we've strengthened our platform and positioned the company for long-term growth." EVERTEC REPORTS THIRD QUARTER 2025 RESULTS Raises full year outlook SAN JUAN, PUERTO RICO – November 6, 2025 – EVERTEC, Inc. (NYSE: EVTC) ("Eve ...

Exhibit 99.1 OneStream Announces Third Quarter 2025 Financial Results BIRMINGHAM, Mich., OneStream, Inc. (Nasdaq: OS), the leading enterprise Finance management platform that modernizes the Office of the CFO by unifying core finance and operational functions -- including financial close, consolidation, reporting, planning and forecasting -- today announced financial results for its third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights "The team delivered another strong quarter, exc ...